Calcific Aortic Valve Stenosis with Aging and Current Development in its Pathophysiology

Abstract

Aortic stenosis is the most common valvular heart disease affecting the elderly. While most patients have a prolonged asymptomatic phase, the development of symptoms ushers in a phase clinical deterioration that often leads to sudden death without an intervention. Treatment of aortic stenosis with valve replacement often relieves the symptoms but still leaves behind a remodeled left ventricle which may not recover. Understanding the pathophysiology of aortic stenosis and realizing that the disease process may be a more active biological entity rather than a passive degenerative process will help us prevent it. This review serves to summarize the latest literature on the pathophysiology of aortic stenosis in the elderly.

Keywords

advanced glycosylation end product - aortic valve disease - atherosclerosis - biomarkers - valvular heart disease - cardiovascular risk factors

Publikationsverlauf

Artikel online veröffentlicht:
02. November 2022

• References

• 1 Carabello BA. Introduction to aortic stenosis. Circ Res 2013; 113 (02) 179-185
• 2 Eveborn GW, Schirmer H, Heggelund G, Lunde P, Rasmussen K. The evolving epidemiology of valvular aortic stenosis. the Tromsø study. Heart 2013; 99 (06) 396-400
• 3 Martinsson A, Li X, Andersson C, Nilsson J, Smith JG, Sundquist K. Temporal trends in the incidence and prognosis of aortic stenosis: a nationwide study of the Swedish population. Circulation 2015; 131 (11) 988-994
• 4 Mathieu P, Boulanger MC. Basic mechanisms of calcific aortic valve disease. Can J Cardiol 2014; 30 (09) 982-993
• 5 Otto CM, Prendergast B. Aortic-valve stenosis–from patients at risk to severe valve obstruction. N Engl J Med 2014; 371 (08) 744-756
• 6 Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res 2011; 108 (11) 1392-1412
• 7 Katz R, Wong ND, Kronmal R. et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis. Circulation 2006; 113 (17) 2113-2119
• 8 Novaro GM, Katz R, Aviles RJ. et al. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J Am Coll Cardiol 2007; 50 (20) 1992-1998
• 9 Zhao Y, Nicoll R, He YH, Henein MY. The effect of statins on valve function and calcification in aortic stenosis: a meta-analysis. Atherosclerosis 2016; 246: 318-324
• 10 Goel SS, Kleiman NS, Zoghbi WA, Reardon MJ, Kapadia SR. Renin-Angiotensin system blockade in aortic stenosis: implications before and after aortic valve replacement. J Am Heart Assoc 2020; 9 (18) e016911
• 11 Ramchand J, Patel SK, Kearney LG. et al. Plasma ACE2 activity predicts mortality in aortic stenosis and is associated with severe myocardial fibrosis. JACC Cardiovasc Imaging 2020; 13 (03) 655-664
• 12 Yan AT, Koh M, Chan KK. et al. Association between cardiovascular risk factors and aortic stenosis: the CANHEART aortic stenosis study. J Am Coll Cardiol 2017; 69 (12) 1523-1532
• 13 Tao G, Kotick JD, Lincoln J. Heart valve development, maintenance, and disease: the role of endothelial cells. Curr Top Dev Biol 2012; 100: 203-232
• 14 Hinton Jr RB, Lincoln J, Deutsch GH. et al. Extracellular matrix remodeling and organization in developing and diseased aortic valves. Circ Res 2006; 98 (11) 1431-1438
• 15 Boström KI, Jumabay M, Matveyenko A, Nicholas SB, Yao Y. Activation of vascular bone morphogenetic protein signaling in diabetes mellitus. Circ Res 2011; 108 (04) 446-457
• 16 Srivatsa SS, Harrity PJ, Maercklein PB. et al. Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J Clin Invest 1997; 99 (05) 996-1009
• 17 Wallby L, Janerot-Sjöberg B, Steffensen T, Broqvist M. T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart 2002; 88 (04) 348-351
• 18 Towler DA. Molecular and cellular aspects of calcific aortic valve disease. Circ Res 2013; 113 (02) 198-208
• 19 Galeone A, Paparella D, Colucci S, Grano M, Brunetti G. The role of TNF-α and TNF superfamily members in the pathogenesis of calcific aortic valvular disease. ScientificWorldJournal 2013; 2013: 875363
• 20 Pawade TA, Newby DE, Dweck MR. Calcification in aortic stenosis: the skeleton key. J Am Coll Cardiol 2015; 66 (05) 561-577
• 21 Miller JD, Chu Y, Brooks RM, Richenbacher WE, Peña-Silva R, Heistad DD. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 2008; 52 (10) 843-850
• 22 Winchester R, Wiesendanger M, O'Brien W. et al. Circulating activated and effector memory T cells are associated with calcification and clonal expansions in bicuspid and tricuspid valves of calcific aortic stenosis. J Immunol 2011; 187 (02) 1006-1014
• 23 Irtyuga O, Malashicheva A, Zhiduleva E. et al. NOTCH1 mutations in aortic stenosis: association with osteoprotegerin/RANK/RANKL. BioMed Res Int 2017; 2017: 6917907
• 24 Foffa I, Ait Alì L, Panesi P. et al. Sequencing of NOTCH1, GATA5, TGFBR1 and TGFBR2 genes in familial cases of bicuspid aortic valve. BMC Med Genet 2013; 14: 44
• 25 Hofmann JJ, Briot A, Enciso J. et al. Endothelial deletion of murine Jag1 leads to valve calcification and congenital heart defects associated with Alagille syndrome. Development 2012; 139 (23) 4449-4460
• 26 Koos R, Brandenburg V, Mahnken AH. et al. Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients. Eur Heart J 2009; 30 (16) 2054-2061
• 27 Di Minno A, Zanobini M, Myasoedova VA. et al. Could circulating fetuin A be a biomarker of aortic valve stenosis?. Int J Cardiol 2017; 249: 426-430
• 28 Lee SH, Choi JH. Involvement of immune cell network in aortic valve stenosis: communication between valvular interstitial cells and immune cells. Immune Netw 2016; 16 (01) 26-32
• 29 Cagirci G, Cay S, Canga A. et al. Association between plasma asymmetrical dimethylarginine activity and severity of aortic valve stenosis. J Cardiovasc Med (Hagerstown) 2011; 12 (02) 96-101
• 30 Matilla L, Roncal C, Ibarrola J. et al. A role for MMP-10 (matrix metalloproteinase-10) in calcific aortic valve stenosis. Arterioscler Thromb Vasc Biol 2020; 40 (05) 1370-1382
• 31 Lutz M, von Ingersleben N, Lambers M. et al. Osteopontin predicts clinical outcome in patients after treatment of severe aortic stenosis with transcatheter aortic valve implantation (TAVI). Open Heart 2017; 4 (02) e000633